ClinicalTrials.gov
public full text
Public Domain
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
carcinomacolorectal-cancerhead-and-neck-neoplasmshead-and-neck-squamous-cell-carcinomapancreas-cancer
The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- TAEST16001 in the Treatment of Soft Tissue Sarcoma#898938
- Study of CM518D1 in Patients With Advanced Solid Tumors#1185822
- Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%#1127733
- A First in Man Study of MABp1 in Patients With Advanced Cancers#1349907
- A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors#1184477
Record · ID 1262705
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive